Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Malar J

Unité de parasitologie, Unité de recherche sur les maladies infectieuses et transmissibles émergentes - UMR 6236, Institut de recherche biomédicale des armées - antenne de Marseille, Allée du Médecin-colonel Jamot, Parc le Pharo, BP 60109, 13262 Marseille Cedex 7, France.

Published: January 2012

Background: One of the major complications of Plasmodium falciparum infection is cerebral malaria (CM), which causes one million deaths worldwide each year, results in long-term neurological sequelae and the treatment for which is only partially effective. Statins are recognized to have an immunomodulatory action, attenuate sepsis and have a neuroprotective effect. Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the activity of mefloquine (MQ) and quinine.

Methods: The efficiency of 40 mg/kg intraperitoneal AVA, alone or in association with MQ, was assessed in an experimental Plasmodium berghei ANKA rodent parasite model of CM and performed according to different therapeutic schemes. The effects on experimental CM were assessed through the evaluation of brain histopathological changes and neuronal apoptosis by TUNEL staining.

Results: AVA alone in the therapeutic scheme show no effect on survival, but the prophylactic scheme employing AVA associated with MQ, rather than MQ alone, led to a significant delay in mouse death and had an effect on the onset of CM symptoms and on the level of parasitaemia. Histopathological findings show a correlation between brain lesions and CM onset. A neuronal anti-apoptotic effect of AVA in the AVA + MQ combination was not shown.

Conclusions: The combination of AVA and MQ therapy led to a significant delay in mouse mortality. There were differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination was administered to mice. When used in combination with MQ, AVA had a relevant effect on the in vivo growth inhibition and clinical outcome of P. berghei ANKA-infected mice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278339PMC
http://dx.doi.org/10.1186/1475-2875-11-13DOI Listing

Publication Analysis

Top Keywords

cerebral malaria
12
ava
8
led delay
8
delay mouse
8
level parasitaemia
8
combination ava
8
combination
5
atorvastatin treatment
4
treatment effective
4
effective combination
4

Similar Publications

The effect of bitter honey against cerebral malaria-induced inflammasome cell death: network pharmacology-based in silico evaluation.

Biomed Khim

December 2024

Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria; College of Health Sciences, Osun State University, Osogbo, Osun State, Nigeria.

Cerebral malaria (CM) is a fatal complication of Plasmodium falciparum infection. The biological and physiological links between CM, inflammation, and inflammasome, point to the complexity of its pathology. Resistance to available and affordable drugs, worsening economic crisis, and urgent need for integration of orthodox with traditional/alternative medicine, actualized the search for sustainable pharmacotherapy.

View Article and Find Full Text PDF

Oxidative stress is a pivotal factor in the pathogenesis of malaria, contributing to the development of conditions such as anemia, respiratory complications, and cerebral malaria. To counteract oxidative damage, we evaluated the effects of vitamin E (α-TOH) and D-α-tocopherol polyethylene glycol succinate 1000 (TPGS) supplementation on parasitemia progression, mortality rate, and blood-brain barrier (BBB) permeability in Plasmodium berghei ANKA-infected mice. The mice were divided into four groups: a control group (untreated and uninfected), an infected group (Pb), a TPGS+Pb group, and an α-TOH+Pb group.

View Article and Find Full Text PDF

Background: Post malaria neurologic syndrome (PMNS) is a rare complication of malaria, usually caused by Plasmodium falciparum. The clinical picture is highly variable and ranges from qualitative disturbances of consciousness and psychosis to damage to the peripheral nerves, usually occurring three to eight weeks after treated malaria.

Case Presentation: We report the case of a 54-year-old male who presented with recurrent clinical symptoms three and a half weeks after severe falciparum malaria.

View Article and Find Full Text PDF

Background: Malaria remains a major public health concern with substantial morbidity and mortality worldwide. In Malaysia, the emergence of Plasmodium knowlesi has led to a surge in zoonotic malaria cases and deaths in recent years. Signs of cerebral involvement have been observed in a noncomatose, fatal case of knowlesi infection, but the potential impact of this malaria species on the brain remains unexplored.

View Article and Find Full Text PDF

The diagnosis of malaria during the autopsy of a decomposed corpse may prove challenging. Macroscopic changes are non-specific and may include, among others, cerebral oedema, pulmonary oedema, hepatosplenomegaly and, on occasion, the presence of petechiae. The most effective diagnostic tools for malaria are the examination of blood smears and the use of rapid immunochromatographic tests.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!